Liver Damage Worries Lead To Further EU Restrictions On Richter’s Esmya

The European Medicines Agency’s pharmacovigilance committee has recommended more restrictions on the use of Richter’s Esmya because of concerns over the risk of serious liver damage.

Liver
The EMA has placed new restrictions on Esmya because of liver safety concerns

Women with liver problems should not take Gedeon Richter PLC’s uterine fibroid treatment Esmya (ulipristal acetate) because the product may have contributed to the development of some cases of serious liver injury. In addition, liver function tests must be carried out before patients are started on a treatment course with the product.

These are two of the recommendations made by the European Medicines Agency’s pharmacogivilance risk assessment committee (PRAC) at its...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet